

October 1st – 2nd | 7am – 11am PST

Register at: <https://forms.gle/YMcVYBBBeaqFHDUR3A>

Friday October 1st:

Joanna Przybyl, McGill University, *“Translational potential of multi-omic profiling of LMS – applications in studying metabolic reprogramming and circulating tumor DNA.”*

Priya Chudasama, German Cancer Research Center (DFKZ), *“Genomic features and linked therapeutic opportunities in LMS.”*

Rebecca Gladdy, University of Toronto, *“Defining the origins of Leiomyosarcoma: implications for prognosis and therapeutic options.”*

Inga-Marie Schaefer, Brigham and Women’s Hospital, *“Highly recurrent tumor suppressor alterations in LMS.”*

Agnieszka Wozniak, KU Leuven, *“Biomarkers of response to eribulin in Leiomyosarcoma patients.”*

Nicolas Llosa, Johns Hopkins University, *“Targeting the immunosuppressive myeloid niche in Leiomyosarcoma for development of effective immunotherapies.”*

John Mullinax, Moffitt Cancer Center, *“Optimizing adoptive cell therapy using TIL for advanced soft tissue sarcoma.”*

Jessica Burns & Valeriya Pankova, Institute of Cancer Research, *“Characterization and functional assessment of Leiomyosarcoma extracellular matrix.”*

Saturday October 2nd:

Patrick Bhola, Dana Farber Cancer Institute, *“Identification of apoptotic sensitizing compounds in Leiomyosarcoma – a rapid ex vivo chemical screen.”*

Adrian Marino-Enriquez, Brigham and Women’s Hospital, *“Therapeutic targeting of genomic instability in Leiomyosarcoma.”*

Tuyen Duong Thanh Nguyen, MD Anderson Cancer Center, *“Reactivating tumor suppressor activity of Retinoblastoma as a novel strategy for soft tissue sarcomas.”*

Corrie Painter, Broad Institute, *“Count Me In: The Leiomyosarcoma Project.”*

Yinyin Yuan, Institute of Cancer Research, *“Co-evolving AI and pathology to target cancer evolution.”*

Ty Subhawong, University of Miami, *“Radiomics in extremity soft tissue sarcoma.”*

Matthew Ingham, Columbia University, *“A Phase II study of Temozolomide and Olaparib in advanced uterine Leiomyosarcoma with a focus on correlative endpoints.”*

Alessandro Gronchi, Istituto Nazionale dei Tumori di Milano, *“Neoadjuvant chemotherapy in high risk dedifferentiated liposarcoma and leiomyosarcoma of the retroperitoneum: the challenge of a randomized academic global trial.”*